PG-01

• Catalog No.: P0024
• CAS Number: 853138-65-5
• M. F.: C28H29N3O2
• M. W.: 439.54876
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 2-[2-(1H-indol-3-yl)-N-methylacetamido]-2-phenyl-N-[4-(propan-2-yl)phenyl]acetamide
• IUPAC Traditional name: 2-[2-(1H-indol-3-yl)-N-methylacetamido]-N-(4-isopropylphenyl)-2-phenylacetamide
• Synonyms: N-Methyl-N-[2-[[4-(1-methylethyl)phenyl]amino]-2-oxo-1-phenylethyl]-1H-indole-3-acetamide; 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N-(4-isopropylphenyl)-2-phenylacetamide

DATABASE IDS

• MDL Number: MFCD03449821
• CAS Number: 853138-65-5

PROPERTIES

• Empirical Formula (Hill Notation): C28H29N3O2
• Purity: ≥98% (HPLC)
• Apperance: white to off-white powder
• Solubility: DMSO: ≥10 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H413
• European Hazard Symbols: Harmful (Xn)
• Risk Statements: 22
• Storage Temperature: -20°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
CFTR mutations are responsible for cystic fibrosis. The most common mutation is ΔF508, but many others exist. Drugs which can correct channel function of a broad range of CFTR mutants are most desirable for clinical development. PG-01 is a potentiator of ΔF508 (Ka 70 nM) as well as mutants G551D and G1349D (Ka 1100 and 40 nM, respectively). Its broad spectrum may make it more desirable than more mutant-specific CFTR correctors.

Description (简体中文)

Biochem/physiol Actions
CFTR mutations are responsible for cystic fibrosis. The most common mutation is ΔF508, but many others exist. Drugs which can correct channel function of a broad range of CFTR mutants are most desirable for clinical development. PG-01 is a potentiator of ΔF508 (Ka 70 nM) as well as mutants G551D and G1349D (Ka 1100 and 40 nM, respectively). Its broad spectrum may make it more desirable than more mutant-specific CFTR correctors.